Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Taisho Pharmaceutical Holdings

Evaluate

Thumbnail
October 20, 2022

Bispecifics move beyond cancer

Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.

Thumbnail
October 16, 2020

Small Galapagos setback prompts a bigger loss of sentiment

A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.

Article image
Vantage logo
March 25, 2020

Making sense of Covid-19 treatment approaches

IGM's Dan Chen, an expert on coronaviruses, speaks about the value of different ways of trying to treat Covid-19.

Article image
Vantage logo
March 19, 2020

First clinical data show biopharma the way against Covid-19

Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.

Article image
Vantage logo
March 18, 2020

A Covid-19 treatment plan slowly emerges

Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.

Article image
Vantage logo
January 07, 2019

Japanese biopharma rules mid-cap returns

Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?

Article image
Vantage logo
December 19, 2018

In, out, in, out, Glaxo shakes consumer health about

Earlier this year Glaxosmithkline looked to be going all-in for consumer health domination, but today it moved to leave the space entirely and focus on the thing that…

Article image
Vantage logo
October 10, 2018

Mid-cap investors see Eastern promise in the third quarter

Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…

Article image
Vantage logo
July 04, 2018

Mid and small caps provide another rocky ride in the second quarter in 2018

Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.

Article image
Vantage logo
July 04, 2018

Mid and small caps provide another rocky ride in the second quarter

Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.

Vantage logo
March 20, 2017

ACC – Jardiance heart benefit looks like a class effect

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up